Efficient and Precise CRISPR/Cas9-Mediated MECP2 Modifications in Human-Induced Pluripotent Stem Cells.

Area of Science:

• Genetics
• Molecular Biology
• Neuroscience

Background:

• Rett syndrome (RTT) is a severe neurodevelopmental disorder caused by mutations in the methyl-CpG binding protein 2 (MECP2) gene.
• MECP2 is an X-linked epigenetic factor essential for neuronal function, and current treatments for RTT are lacking.

Purpose of the Study:

• To develop and validate a CRISPR/Cas9-based gene editing strategy for correcting MECP2 mutations.
• To assess the efficiency of homologous recombination (HR) for MECP2 gene targeting in human cells and induced pluripotent stem cells (iPSCs).

Main Methods:

• Utilized CRISPR/Cas9 technology to target and correct disease-relevant regions within the MECP2 gene, specifically exon 4.
• Introduced a known pathogenic MECP2 mutation (R270X) into human iPSCs to create a disease model.
• Employed homologous recombination (HR) to repair MECP2 mutations in patient-derived iPSCs.

Main Results:

• Achieved homologous recombination (HR) efficiencies ranging from 20% to 30% in human cell lines and iPSCs.
• Successfully repaired MECP2 mutations with high efficiency in human mutant iPSCs using the CRISPR/Cas9 system.

Conclusions:

• Developed a novel CRISPR/Cas9 strategy for precise MECP2 gene targeting.
• This approach offers a potential therapeutic avenue for Rett syndrome and facilitates the creation of iPSC-based disease models for further research.